Physician profile
Peter E Legnani
NPI 1942219548
$27,222.54
in general payments reported to CMS, 2019-2025
38 companies · $5,796 in 2025
The $5,796 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,688 · 2020: $2,492 · 2021: $3,456 · 2022: $3,585 · 2023: $4,024 · 2024: $4,181 · 2025: $5,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,850.92 |
| Education | $150.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,019.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,175.78 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $3,479.75 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $2,544.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,266.45 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $2,187.89 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $1,413.05 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $752.43 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $595.61 | 2019-2023 | Rebyota, Clenpiq |
| Janssen Scientific Affairs, LLC | $579.67 | 2025 | Tremfya |
| Ucb, INC. | $539.63 | 2019-2020 | |
| Amgen INC. | $396.53 | 2020-2025 | Avsola, Amjevita, Uplizna |
| Daiichi Sankyo INC. | $377.55 | 2020-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $287.40 | 2019-2021 | |
| Ardelyx, INC. | $277.92 | 2023-2025 | Ibsrela |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $260.05 | 2023-2025 | Dupixent |
| Endo Pharmaceuticals INC. | $228.40 | 2019-2022 | |
| Boston Scientific Corporation | $184.56 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.97 | 2023-2024 | Cyltezo |
| Allergan, INC. | $166.58 | 2019 | |
| Lilly USA, LLC | $154.01 | 2024-2025 | Omvoh |
| Organon LLC | $135.52 | 2024-2025 | Hadlima |
| Braintree Laboratories, INC. | $132.41 | 2019-2024 | Sutab, Suflave |
| Vivus LLC | $126.16 | 2023-2025 | Qsymia |
| Sandoz INC. | $105.49 | 2024-2025 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $92.30 | 2020-2023 | |
| Redhill Biopharma INC. | $90.13 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Celltrion USA INC. | $81.82 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $76.76 | 2024 | Voquezna |
| Shire North American Group INC | $68.64 | 2019 | |
| Romark Laboratories, Lc | $54.18 | 2019 | |
| Exact Sciences Corporation | $52.54 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $48.52 | 2024-2025 | Vowst |
| Fujifilm Healthcare Americas Corporation | $25.28 | 2021 | |
| Ambu INC. | $23.92 | 2024 | |
| Gilead Sciences, INC. | $20.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Legnani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.